Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055480312> ?p ?o ?g. }
- W2055480312 endingPage "905.e3" @default.
- W2055480312 startingPage "890" @default.
- W2055480312 abstract "BackgroundTwo new therapies for fecal incontinence (FI) are now available: non–animal stabilized hyaluronic acid and dextranomer copolymer (NASHA/Dx) and sacral nerve stimulation (SNS).PurposeThis study aimed to determine the cost-effectiveness of NASHA/Dx compared with SNS and conservative therapy (CT) for the treatment of FI after CT failure.MethodsDecision tree models with Markov subbranches were developed to compare all direct costs and outcomes during a 3-year period from the viewpoint of the US third-party payer. Costs (in 2013 US dollars) of devices, medical and surgical care, and hospitalization were included. Outcomes included quality-adjusted life-years (QALYs) and incontinence-free days (IFDs). Both costs and outcomes were discounted at an annual rate of 3%. The incremental cost-effectiveness ratio was calculated for each outcome. One-way and probabilistic sensitivity analyses were performed to examine robustness of results and model stability. A budget impact analysis was also undertaken to estimate the potential cost and savings of NASHA/Dx for a payer with 1,000,000 covered lives.ResultsFor the 3-year cost-effectiveness models, the expected cost was $9053 for CT, $14,962 for NASHA/Dx, and $33,201 for SNS. The numbers of QALYs were 1.769, 1.929, and 2.004, respectively. The numbers of IFDs were 128.8, 267.6, and 514.8, respectively. The incremental cost-effectiveness ratios per additional IFD gained were $42.60 for NASHA/Dx vs CT, $73.76 for SNS vs NASHA/Dx, and $62.55 for SNS vs CT. The incremental costs per QALY gained were $37,036 for NASHA/Dx vs CT, $244,509 for SNS vs NASHA/Dx, and $103,066 for SNS vs CT. The budget impact analysis evaluated the financial effect on the health care system of the use of NASHA/Dx and SNS. For the scenarios evaluated, when all of the patients receive NASHA/Dx, the net annual effect to the health care payer budget ranged from $571,455 to $2,857,275. When all of the patients receive SNS, the net annual effect to the health care payer budget ranged from $1,959,323 to $9,796,613.ConclusionBoth NASHA/Dx and SNS have produced significant improvements in FI symptoms for affected patients. NASHA/Dx is a cost-effective and more efficient use of resources for the treatment of FI when compared with SNS. The budget impact analysis suggests that although reimbursement for NASHA/Dx treatment initially adds costs to the health care system, it is significantly less expensive than SNS for patients who are candidates for either treatment." @default.
- W2055480312 created "2016-06-24" @default.
- W2055480312 creator A5022975113 @default.
- W2055480312 creator A5054352873 @default.
- W2055480312 creator A5078210040 @default.
- W2055480312 creator A5091121897 @default.
- W2055480312 date "2014-06-01" @default.
- W2055480312 modified "2023-09-27" @default.
- W2055480312 title "Three-Year Cost-effectiveness Model for Non–Animal Stabilized Hyaluronic Acid and Dextranomer Copolymer Compared With Sacral Nerve Stimulation After Conservative Therapy for the Management of Fecal Incontinence" @default.
- W2055480312 cites W1843185013 @default.
- W2055480312 cites W1986404682 @default.
- W2055480312 cites W1993791285 @default.
- W2055480312 cites W1993972569 @default.
- W2055480312 cites W2011144550 @default.
- W2055480312 cites W2013368928 @default.
- W2055480312 cites W2013471072 @default.
- W2055480312 cites W2015292174 @default.
- W2055480312 cites W2033835998 @default.
- W2055480312 cites W2034783885 @default.
- W2055480312 cites W2035418465 @default.
- W2055480312 cites W2037196469 @default.
- W2055480312 cites W2037213655 @default.
- W2055480312 cites W2038592300 @default.
- W2055480312 cites W2046591329 @default.
- W2055480312 cites W2048835392 @default.
- W2055480312 cites W2063613482 @default.
- W2055480312 cites W2064602219 @default.
- W2055480312 cites W2070422380 @default.
- W2055480312 cites W2078696662 @default.
- W2055480312 cites W2085584147 @default.
- W2055480312 cites W2115002011 @default.
- W2055480312 cites W2119674820 @default.
- W2055480312 cites W2129699362 @default.
- W2055480312 cites W2135068662 @default.
- W2055480312 cites W2137435686 @default.
- W2055480312 cites W2143811824 @default.
- W2055480312 cites W2147593716 @default.
- W2055480312 cites W2150516257 @default.
- W2055480312 cites W2166835422 @default.
- W2055480312 cites W2322967343 @default.
- W2055480312 cites W2323245213 @default.
- W2055480312 cites W2330892675 @default.
- W2055480312 cites W2333269694 @default.
- W2055480312 cites W2404205350 @default.
- W2055480312 cites W4376595362 @default.
- W2055480312 doi "https://doi.org/10.1016/j.clinthera.2014.04.010" @default.
- W2055480312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24815061" @default.
- W2055480312 hasPublicationYear "2014" @default.
- W2055480312 type Work @default.
- W2055480312 sameAs 2055480312 @default.
- W2055480312 citedByCount "7" @default.
- W2055480312 countsByYear W20554803122014 @default.
- W2055480312 countsByYear W20554803122016 @default.
- W2055480312 countsByYear W20554803122017 @default.
- W2055480312 countsByYear W20554803122019 @default.
- W2055480312 countsByYear W20554803122022 @default.
- W2055480312 crossrefType "journal-article" @default.
- W2055480312 hasAuthorship W2055480312A5022975113 @default.
- W2055480312 hasAuthorship W2055480312A5054352873 @default.
- W2055480312 hasAuthorship W2055480312A5078210040 @default.
- W2055480312 hasAuthorship W2055480312A5091121897 @default.
- W2055480312 hasBestOaLocation W20554803121 @default.
- W2055480312 hasConcept C105702510 @default.
- W2055480312 hasConcept C126894567 @default.
- W2055480312 hasConcept C141071460 @default.
- W2055480312 hasConcept C2776162027 @default.
- W2055480312 hasConcept C2777529286 @default.
- W2055480312 hasConcept C2779234561 @default.
- W2055480312 hasConcept C29456083 @default.
- W2055480312 hasConcept C3017551082 @default.
- W2055480312 hasConcept C3018664633 @default.
- W2055480312 hasConcept C54355233 @default.
- W2055480312 hasConcept C71924100 @default.
- W2055480312 hasConcept C86803240 @default.
- W2055480312 hasConceptScore W2055480312C105702510 @default.
- W2055480312 hasConceptScore W2055480312C126894567 @default.
- W2055480312 hasConceptScore W2055480312C141071460 @default.
- W2055480312 hasConceptScore W2055480312C2776162027 @default.
- W2055480312 hasConceptScore W2055480312C2777529286 @default.
- W2055480312 hasConceptScore W2055480312C2779234561 @default.
- W2055480312 hasConceptScore W2055480312C29456083 @default.
- W2055480312 hasConceptScore W2055480312C3017551082 @default.
- W2055480312 hasConceptScore W2055480312C3018664633 @default.
- W2055480312 hasConceptScore W2055480312C54355233 @default.
- W2055480312 hasConceptScore W2055480312C71924100 @default.
- W2055480312 hasConceptScore W2055480312C86803240 @default.
- W2055480312 hasIssue "6" @default.
- W2055480312 hasLocation W20554803121 @default.
- W2055480312 hasLocation W20554803122 @default.
- W2055480312 hasOpenAccess W2055480312 @default.
- W2055480312 hasPrimaryLocation W20554803121 @default.
- W2055480312 hasRelatedWork W1586374228 @default.
- W2055480312 hasRelatedWork W2003938723 @default.
- W2055480312 hasRelatedWork W2047967234 @default.
- W2055480312 hasRelatedWork W2118496982 @default.
- W2055480312 hasRelatedWork W2130554639 @default.
- W2055480312 hasRelatedWork W2364998975 @default.
- W2055480312 hasRelatedWork W2369162477 @default.